Isis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. PP patients treated with ISIS-GCGRRx in this study also achieved a mean reduction of up to 74.9 µmol/L in fructosamine. In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.
Recent IONS News
- Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome • PR Newswire (US) • 07/22/2024 11:00:00 AM
- Ionis to hold second quarter 2024 financial results webcast • PR Newswire (US) • 07/19/2024 12:24:00 PM
- Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease • PR Newswire (US) • 07/18/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:03:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:03:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:02:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:02:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:02:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:02:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:11:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:06:34 PM
- Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome • PR Newswire (US) • 07/08/2024 11:05:00 AM
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed • PR Newswire (US) • 06/25/2024 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:29:02 PM
- Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema • PR Newswire (US) • 06/18/2024 11:00:00 AM
- Ionis to present at TD Cowen Genetic Medicines & RNA Summit • PR Newswire (US) • 06/17/2024 08:09:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 02:59:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:33:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 11:15:31 AM
- Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema • PR Newswire (US) • 05/31/2024 11:00:00 AM
- Ionis to hold donidalorsen Phase 3 data webcast • PR Newswire (US) • 05/28/2024 11:00:00 AM
- New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) • PR Newswire (US) • 05/23/2024 11:00:00 AM
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • GlobeNewswire Inc. • 05/16/2024 11:30:14 AM
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • PR Newswire (US) • 05/16/2024 11:30:00 AM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM